ABCL - AbCellera

-

$undefined

N/A

(N/A)

AbCellera NasdaqGS:ABCL AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Location: 150 West 4th Ave, Vancouver, BC, V5Y 1G6, Canada | Website: https://www.abcellera.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

65.52M

Cash

605.3M

Avg Qtr Burn

-19.6M

Short % of Float

11.12%

Insider Ownership

22.97%

Institutional Own.

44.71%

Qtr Updated

03/31/25